Update on Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO), headquartered in Bethesda, MD, is a clinical stage biotechnology company that develops personalized cancer vaccines to treat a wide range of solid tumor cancers. The company has a market capitalization of over $35 million and trades less than 1.5 million shares daily based on their 30-day average. Today NWBO share volumes are trading at four times their averages.

At the center of their strategic advantage is the DCVax technology platform. DCVax uses activated dendritic cells (the master cells of the immune system) to educate the body’s entire immune system on how to attack a cancer. Conventional cancer treatments use one active agent to hit one target on the cancer while DCVax uses many active agents to hit many targets on the cancer. Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) believes there are three aspects of the DCVax system that have indicated promise for the technology. First, the DCVax system mobilizes the entire immune system, not just a single immune agent. Secondly, DCVax targets all of the biomarkers on a cancer patient’s tumor, not just one. Lastly, DCVax uses the patient’s own tumor to develop the specific treatment. This highly customized approach has, to date, produced positive results. DCVax has achieved clinical benefits. Over 80% of the patients who were treated with the DCVax system approach experienced a longer delay in the cancer’s progression and an extension of survival when compared to patients who received a more traditional standard of care.

Three drug candidates are in the Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) pipeline. DCVax-L is in Phase 3 trails for the indication of brain cancer and in Phase 2 trials for the indication of metastatic overian cancer. DCVax-Direct has a Phase 1/2 trial underway currently. DCVax-Prostate has been cleared by the FDA for Phase 3 trials and Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) is currently searching for an appropriate partner to begin the trial.

Over a month ago, Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) closed on a $7.5 million fund raise with several institutional investors. The common shares were priced at $0.26 per share while the class C warrants were priced at an exercise price of$0.25 with $0.01 to be paid per share when exercised. This was done in order to ensure all of the investor’s equity stayed below 5%.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading.

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)

Edison, NJ-based ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) shares plummeted on news that the Edison, NJ-based biotech firm would be pricing shares in their public offering at $1.00 per share. CTRV shares began their drop on April 20 and yesterday shares were worth half of their April 20th highs. Volumes have been heavy – today they are trading at about five times their normal average daily volume.

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) is seeking to raise $12 million, gross, for R&D, including on-going clinical trials, as well as general corporate purposes. The biotech firm also announced that the new funds may be used for possible acquisitions of other companies, products, or technologies though it stated that no such activity is currently under way.

12 million shares will be offered at the price of $1.00. Warrants will also be offered that could purchase an additional six million shares. The warrants for ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) will be immediately exercisable and have a five-year term with an exercise price of $1.25 per share. Investors should note with caution that no market will exist for the warrants and none is forecast to develop. Canaccord Genuity is the sole book-running manager and Maxim Group LLC is the co-manager for the offering.

The current focus of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) is developing a curative therapy for the hepatitis B virus. It currently has two drugs under development for that purpose – TXL (formerly known as CMX157) and CRV431. The company also has Valnivudine in Phase 3 clinical trials. Valnivudine was developed for the treatment of Herpes zester – commonly known as “shingles”.

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) is a pre-revenue company. In the past share dilution has been heavy. There were nine million shares outstanding in 2013. More shares were issued in each of the following years and in 2016 the company reported that there were 27.06 million CRTV shares outstanding. CRTV’s share price performance has reflected the lack of sales and dilutive share offerings. YTD CRTV shares are down 28.33%, down 23.21% for the year, and down over 67% from their 52-week high of $2.65. Despite CRTV share performance, those few firms that follow ContraVir give it a “Hold” rating with a consensus price estimate of $4.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance

INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) Announces Marketed Offering of Common Shares

INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF)

INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF), a biopharmaceutical company engaged in research and development of cannabinoid-based drug has announced filing a preliminary short form prospectus with securities regulatory agencies in the provinces of Ontario, Alberta, and British Columbia in connection to the company’s public offering .

The offering will be done on an underwritten basis under the leadership of Canaccord Genuity Corp. Roth Capital Partners, LLC has been appointed to act as the placement manager for sales of common shares in the United States.

INMED PHARMACEUTIC has agreed to grant an over-allotment option to the Underwriters which will be exercisable in part or whole for a 30-day period from the closing date. The offering will close in May 17, 2017 and will be subject to Underwriters and the Company signing an underwriting agreement as well as the company securing all required regulatory approvals including the Canadian Securities Exchange approval.

The proceeds from the offering will be used to support the ongoing development of INM-750 for Epidermolysis Bullosa treatment. The proceeds will also go towards funding the company’s other research programs as well as the company’s general expenses.

INMED PHARMACEUTIC has announced that its shareholders have approved a number things – among them a new option plan for its stock dubbed the “2017 Option Plan” as well as an amendment and restatement of corporate Articles. These changes were made in a special shareholders’ meeting held recently.

Additionally, the company’s shareholders ratified changes in the authorized share structure of the company to do away with Class A and B Preference shares. The company will instead create preferred shares minus par value. The terms of the newly set up 2017 Option Plan, the changes to the authorized share structure of the company as well as the New Articles have been summarized in the February 22, 2017 management information circular of the company. A copy of the same has been filed at SEDAR. The company will file the New Articles with the Canadian Securities Exchange as well as SEDAR.

In addition to filing the new changes, the company also filed a results report from a voting exercise on all the resolutions that were voted for during the special meeting.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.

Eastgate Biotech Corp (OTCMKTS:ETBI) Engages Gunpowder Capital Corp

Eastgate Biotech Corp (OTCMKTS:ETBI)

Eastgate Biotech Corp (OTCMKTS:ETBI) has entered into a number of agreements with Gunpowder Capital Corp.

As part of the agreement, Gunpowder Capital Corp will continue acting as Eastgate’s financial advisor and will also assist Eastgate in several compliance matters in relation to the ongoing public listing as well as helping in administrative matters.

As compensation for work done, Gunpowder Capital Corp will be paid C$15,000. After listing on the Canadian Stock Exchange, Gunpowder Capital will continue serving Eastgate for at least six months as an advisor and will be paid a monthly fee of C$5,000.00. Additionally, after listing, Gunpowder Capital will be entitled to 8% of Eastgate’s outstanding common shares.

Gunpowder Capital Corp will also lend Eastgate $78,000.00 USD at an annual interest rate of 14%. Eastgate will use one its officers as a personal guarantor for the loan which will be convertible at any time into common shares at the rate of $0.05 per share.

As part of the agreement, Gunpowder Capital will be entitled to One Million warrants of Eastgate’s common stock. The warrants will be exercisable for a period of three years and will allow Gunpowder Capital to purchase 1,000,000 of Eastgate’s common shares at the rate of $0.05 per share.

OMNI Surgery and Anti-Aging Centre, EastGate’s recent acquisition, has announced the appointment of Dr. Ishaan Sundar as its Medical Director. Dr. Sundar is a graduate of the Laser Sheer Training Academy, American Cosmetic Cellular Medicine Association, and American Academy of Aesthetic Medicine and specializes in Injectable Placements. Dr. Sundar has over 20 years of experience and practice at OMNI state-of-the-art centre. He has distinguished career and extensive experience in Critical Care Medicine (ICU, CCU). He will be in charge of surgical and medical operations at the only anti-aging and fee-for-service surgical centre in Saskatchewan.

OMNI Surgery and Anti-Aging Centre is located in the underserved market in Saskatchewan, Canada and has a lot of potential for growth. EastGate’s head of Global Business Development and Licensing, and former OMNI Surgery owner Bill Abajian said Dr. Sundar’s experience as a physician will be valuable to the company’s management and leadership team.

EastGate CEO, Anna Gluskin, said EastGate Biotech gets around $2 million from OMNI Surgery in form of assets. Addition that their main goal is to replicate OMNI Surgery + Anti-Aging clinics in all emerging markets.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.

Capricor Therapeutics Inc (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR)

Beverly Hills, CA-based Capricor Therapeutics Inc (NASDAQ:CAPR) saw its share volumes explode tofay. The micro-cap biotechnology company has a 30-day average daily share volume of just 68,450 but by 1:30 PM EST over three million shares had traded based on an announcement by the company that top-line results from a safety and efficacy trial were positive. CAPR shares are up over 5% on the news.

Capricor Therapeutics Inc (NASDAQ:CAPR) lead drug candidate is CAP-1002 – an “off the shelf” cell therapy. This drug is in development for the treatment of heart disease associated with Duchenne muscular dystrophy (DMD) and adult cardiac conditions. Capricor’s technology had an early and powerful beginning. In their CADUCEUS clinical trial, a single administration of the drug showed significant reductions in the size of the scar that has resulted from a heart attack. Also observed were significant increases in the muscle mass of the affected area.

This morning, Capricor Therapeutics Inc (NASDAQ:CAPR)announced positive top-line results from a safety and efficacy analysis of six months’ worth of data generated from a randomized Phase 1/2 HOPE clinical trial of CAP-1002 for the treatment of patients afflicted with DMD. The single-dose trial was conducted using three health care centers and 25 patients who all are experiencing advanced cardiac disease. Those patients treated with CAP-1002 showed statistically significant improvement when compared to normal care controls in terms of cardiac and upper limb functionality. Importantly, these results corroborate pre-clinical data. Capricor Therapeutics Inc (NASDAQ:CAPR) plans to meet with the U.S. Food and Drug Administration (FDA) and request the designation of a Breakthrough Therapy or a Regenerative Medicine Advanced Technology (RMAT).

Capricor Therapeutics Inc (NASDAQ:CAPR) shareholders have seen better days. The stock is now trading above $3 and was stuck below $5 for most of the past 1 ½ years. Recently institutional investors have slashed their positions by over 34% but shares held by other insiders have held firm. While CAPR shares are up over 16% YTD, they are down over 23% for the year.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Results Boost Catabasis Pharmaceuticals Inc (NASDAQ:CATB) in Pre-Mkt

Catabasis Pharmaceuticals Inc (NASDAQ:CATB)

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) closed trading on Friday at $1.45 but has gapped up in today’s pre-market and hit a high of $2.25 – a gain of over 55%. Pre-market volumes have been heavy as over 625,000 shares have traded hands by 8:40 AM EST. Despite this morning’s massive gain, CATB shares are still down over 58% YTD, and 70% for the year.

The market’s demand for shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) seem to be rooted in this morning’s press release by the biotech company regarding the additional results, deemed favorable, across five functional assessments in the Move DMD trial. Results were announced at the American Academy of Neurology’s 69th Annual Meeting.

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) MoveDMD trial is a three-part clinical trial determing the safety and efficacy of edasalonexent in males aged 4-7 who are afflicted with Duchenne muscular dystrophy (DMD). During the treatment period with edasalonexent, positive numerical changes were observed when compared to the same tests being performed with a period when dosing was not done. A regimen of 100 mg/day of edasalonexent showed improvements across the same five assessments when compared to the placebo group. Cambridge, MA-based Catabasis Pharmaceuticals Inc (NASDAQ:CATB) will release the next clinical trial update in Q3 of 2017.

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) focuses on the discovery, development, and commercialization of therapies designed to treat inflammatory and metabolic diseases. In addition to the drug described above for thetreatment of DMD, the biotech has drug candidates addressing illnesses such as hyercholeserolemia and hypertriglyceridemia. The company has collaboration agreements with muscular dystrophy associations and Serepta Therapeurics (SRPT).

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) went public in 2015 and hit a high around $17 but has declined from those levels and traded, mostly, below $2 for all of 2017. The 52-week high is $7.89 and the 52-week low is $1.08. CATB shareholders had an EPS loss of (-$2.13) in 2015 and that figure stayed almost the same for 2016 when the company reported an EPS loss of (-$2.22). At the same time, there has been share dilution. In 2014 there were 13.85 million shares, then 15.34 million shares outstanding in 2015, and for 2016 there were 16.23 million shares outstanding. Four firms follow Catabasis and three assign the shares a rating of “Strong Buy” while one rates CATB shares as a “Hold”. Their consensus target price is $6.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading.

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) Eyes $8 Billion Industry With Aurora Drops

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF)

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) has started selling a new set of ingestible cannabis oils as Canada inches a step closer to legalizing the recreational use of Marijuana. Dubbed Aurora Drops, the three distinct cannabis oils will go on sale for $115 per bottle. However, clients under the company’s compassionate pricing program will be able to buy it at $80 a bottle.

Aurora Unveils Aurora Drops

The launch of the three distinct oils marks yet another milestone for the Canadian company which is turning heads in the multibillion-cannabis space. Chief Global business development officer, Neil Belot, expects Aurora Drops to significantly bolster the company’s top and bottom-line results.

“We have produced a sizeable inventory of Aurora Drops for our domestic medical client base, and will be continuing to ramp up production in order to address the strong demand we anticipate for high-quality, high-margin derivative products, manufactured under the rigorous Aurora Standards regarding processes, testing, and transparency,” said Mr. Belot.

Aurora Peloton Acquisition

The launch of Aurora drops comes on the heels of the company completing the acquisition of Peloton Pharmaceuticals, which is currently constructing a 40,000 square foot cannabis production facility. Once complete the facility will further bolster Aurora cannabis production capacity, allowing it to produce more products to meet the ever-growing demand in the market.

Peloton’s acquisition also provides Aurora with another low-cost production capacity as it continues to ramp up. The acquisition is also expected to bolster the company’s e-commerce strategy according to CEO, Terry Booth.

Canada Marijuana Legalization

The launch of Aurora Drops and acquisition of Peloton could not have come at a better time as the legalization drive continues to gather momentum. Canada could become the second country after Uruguay to legalize recreational use of Marijuana – a move that could result in the creation of an $8 billion industry. The push is already fuelling investment in the industry as companies look to accrue a substantial amount of market share on the back of growing demand for cannabis products.

According to estimates, demand Canada’s adult market could approach 600,000 kg of cannabis. This represents a significant increase from the current levels and one of the reasons why companies are investing big on production facilities. Aurora is currently constructing an 800,000 square foot marijuana production facility dubbed Aurora Sky.

CANOPY GROWTH CORP COM NPV (OTCMKTS:TWMJF) and APHRIA INC COM NPV (OTCMKTS:APHQF) are the other companies that are rivaling Aurora cannabis on acquisitions and development of cannabis production facilities.

Aurora Cannabis was unchanged in Monday trading session closing the day at $2.05 a share.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.

PhaseRx Inc (NASDAQ:PZRX) Rockets

PhaseRx Inc (NASDAQ:PZRX)

PhaseRx Inc (NASDAQ:PZRX) shares rocketed from the open and closed the regular trading session up over 50%. PZRX gained $0.67 from its close Friday at $1.24 to close today at $1.91. The large move was unusual for a stock that has an Average True Range of just $0.14. The gain was on the back of heavy volume. PZRX traded over 4.2 million shares but the average daily volume for PZRX is just 79,370.

Motivation for traders and investors seems to be from the European equivalent of the Food and Drug Administration, the “European Medicines Agency” (EMA), designating one of PhaseRx’s drug candidates the status of “Orphan Drug”. Such status allows for a more streamlined clinical trial pathway as well as a 10-year market exclusivity for the indication if the drug is ultimately approved for commercialization. The indication that allowed PhaseRx Inc (NASDAQ:PZRX) to receive the Orphan Drug status is ornithine transcarbamylase deficiency – a rare inherited disorder that causes ammonia to accumulate in the blood.

PhaseRx Inc (NASDAQ:PZRX) focuses on developing and commercializing mRNA products for inherited liver diseases. The technology behind Phase Rx’s efforts replaces missing or defective enzymes inside liver cells. The method by which this is achieved is called intracellular enzyme replacement therapy which targets the synthesis of delivered mRNA specifically to the cells of the liver.

PhaseRx Inc (NASDAQ:PZRX) went public in 2016 and at one time traded over $5.50. It has slid significantly from that level but has broken-even for the year and is actually up over 23% YTD. PZRX shares are not able to be traded with options and institutions own more than half the outstanding shares. One of the interesting stats surrounding the stock is that the company is reported to have $1.37 per share on hand. For a stock that is trading below $2, that should bring a level of comfort to some investors. Analysts are mostly neutral on the shares but have given PZRX a consensus price target of $10 – or about 500% above current levels.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) To Give Keynote in Monaco

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP)

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is aiming to capitalize on the growing social acceptance of cannabinoid medical products through its wholly-owned Israeli subsidiary World Cannabis Ltd. OWC plans to discover, develop and commercialize cannabis therapeutics to address critical medical conditions. OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is also developing a cannabis soluble tablet and topical cream.

Cannabis has a history that stretches back over 10,000 years in Asia. The earliest uses were for food and clothing. The Chinese first discovered the medicinal effects of cannabis and used it, mixed with wine, as an anesthetic. Other uses, such as for hair loss or constipation, were also treated with the plant but no determination of its efficacy is recorded. What we do know is that cannabis has such a strong presence in traditional Chinese medicine that one book named it as one of the 50 fundamental herbs in Chinese medicine.

As a result of its frequent use and reputation, medicinal practitioners all over the world adopted the use of cannabis through the ages. It was a key treatment for healthcare practitioners in Ancient Egypt, Greece, and Rome. Its use has been documented during the Middle Ages. But cannabinoid medical products hit the mainstream in Jamaica when Dr. Lockhart and Manley West noticed that Jamaicans had an unusually low rate of glaucoma in their population. After some scientific research, they received permission to market the drug Canasol. More recently many U.S. states have approved the use of medical marijuana and cannabinoid products.

Enter OWC Pharmaceutical Research Corp (OTCMKTS:OWCP). OWC is currently working to develop formulations utilizing cannabinoids. So far the company has entered into a collaboration agreement with a major Israeli medical center. The collaboration includes initiating pre-clinical and clinical studies to determine the effectiveness of cannabidiol and tetrahydrocannabinol, or combinations of the two, to treat multiple myeloma, psoriasis, and fibromyalgia. OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has filed eight patents to protect and support their efforts.

How seriously are their efforts being taken? Just recently the company announced their invitation to present at the Spring Edition of the Monaco Growth Forum. Dr. Baruch will present OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) approach to the forum and he will also serve as the keynote speaker at a cocktail reception for the forum participants.

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is very liquid – the average daily volume is over three million shares.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) Announces Registered Direct Offering Of $7.5 Million

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) has announced entering into definitive agreements with a number of institutional investors for a registered offering that is expected to raise $7.5 million in gross proceeds. Northwest Biotherapeutics is a biotechnology company specializing in the development of DCVax® personalized immune treatment for solid tumor cancers.

According to the terms of the transaction, Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) is expected to sell around 28.8 million shares of common stock at a price of $0.26 per share. In addition, the investors are entitled to Class A warrants with a five-year term to buy up to around 21.6 million shares of common stock at a price of $0.26 per share. The investors are also entitled to Class B warrants for three months to purchase up to around 21.6 million shares at a price of $1.00 per share. Investors will also get Class C warrants at a price of $0.26 per share which is exercisable immediately.

In yet another offering, Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) signed Note Repurchase Agreement with a number of investors attached to Whitebox for the company’s $11 million convertible senior notes. The two companies have agreed on a time payment method in the line with Northwest Biotherapeutics’ development schedule as well as increasing constant payment for a period of four months. As part of the agreement and a consideration of the changes, Whitebox will be entitled to Northwest Biotherapeutics’ stock.

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) is one of the leading biotechnology companies engaged in the development of personalized immunotherapy drugs used in the treatment of cancers with a more effective impact than the prevailing treatments. As opposed to chemotherapies, the company’s products are made without the associated toxicities. In addition the products are marketed at cost-effective prices in Europe and the United States. Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) has a wide technological platform for DCVax dendritic cell-based vaccines. Its lead project is a 331-patient Phase III trial used to treat newly diagnosed Glioblastoma multiforme (GBM). Glioblastoma multiforme is a very lethal and aggressive type of brain cancer and is an “orphan disease.” In addition, the company is also in the process of developing a Phase I/II trial with DCVax-Direct used in treatment of all forms of tumor cancers which cannot be cured through conventional operations. The company has completed the 40% Phase I part of the trial and is currently preparing to start the Phase II part.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.